ENTRY       D10446                      Drug
NAME        Margetuximab (USAN/INN);
            Margetuximab-cmkb;
            Margenza (TN)
PRODUCT     MARGENZA (MacroGenics)
FORMULA     C6484H10010N1726O2024S42
EXACT_MASS  145782.1685
MOL_WEIGHT  145871.938
SEQUENCE    (Heavy chain)
            QVQLQQSGPE LVKPGASLKL SCTASGFNIK DTYIHWVKQR PEQGLEWIGR IYPTNGYTRY
            DPKFQDKATI TADTSSNTAY LQVSRLTSED TAVYYCSRWG GDGFYAMDYW GQGASVTVSS
            ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
            GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELVGG
            PSVFLLPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPPEEQYN
            STLRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
            LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPLV LDSDGSFFLY SKLTVDKSRW
            QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
            (Light chain)
            DIVMTQSHKF MSTSVGDRVS ITCKASQDVN TAVAWYQQKP GHSPKLLIYS ASFRYTGVPD
            RFTGSRSGTD FTFTISSVQA EDLAVYYCQQ HYTTPPTFGG GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H'22-H'96, L23-L88, L'23-L'88, L134-L194, L'134-L'194, H147-H203, H'147-H'203, H223-L214, H'223-L'214, H229-H'229, H232-H'232, H264-H324, H'264-H'324, H370-H428, H'370-H'428; Glycosylation site: Asn-H300, Asn-H'300)
  TYPE      Peptide
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03158  HER2 inhibitor
REMARK      ATC code: L01FD06
            Product: D10446<US>
EFFICACY    Antineoplastic, Anti-HER2 antibody
  DISEASE   Breast cancer (HER2 positive) [DS:H00031]
  TYPE      Monoclonal antibody
TARGET      ERBB2* (HER2, CD340) [HSA_VAR:2064v1] [HSA:2064] [KO:K05083]
  PATHWAY   hsa04012(2064)  ErbB signaling pathway
            hsa05200(2064)  Pathways in cancer
            hsa05224(2064)  Breast cancer
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
                 L01FD06 Margetuximab
                  D10446  Margetuximab (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Margetuximab
                D10446  Margetuximab (USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03158  HER2 inhibitor
                 D10446  Margetuximab
            Drug classes [BR:br08332]
             Antineoplastic
              DG03158  HER2 inhibitor
               D10446  Margetuximab
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               EGFR family
                ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
                 D10446  Margetuximab (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10446
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10446
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10446
DBLINKS     CAS: 1350624-75-7
            PubChem: 172232539
///
